Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration. (February 2019)

• Record Type: Journal Article
• Authors: De Clercq, Erik
• Is Part Of: Antiviral chemistry & chemotherapy. Volume 27(2019)
• Publication Date: 2019-02
• Subjects: CXCR4 -- Mozobil® -- AMD3100 -- stem cells -- NHL -- MM -- WHIM; Antiviral agents -- Periodicals; Chemotherapy -- Periodicals; 615.7924
• DOI: 10.1177/2040206619829382
• Languages: English
• ISSNs: 0956-3202

Abstract

AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34 + stem cells from the bone marrow into the peripheral blood stream. In December 2008, AMD3100 was formally approved by the US FDA for autologous transplantation in patients with Non-Hodgkin's Lymphoma or multiple myeloma. It may be beneficially used in various other malignant diseases as well as hereditary immunological disorders such as WHIM syndrome, and physiopathological processes such as hepatopulmonary syndrome.